Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coagulation01:06

Coagulation

1.4K
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
1.4K
Coagulation01:09

Coagulation

10.4K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
10.4K
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

322
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
322
Decreasing Function01:27

Decreasing Function

267
A decreasing function describes a relationship where the output consistently declines as the input increases. This means that for any two input values, if one is greater than the other, the corresponding output is smaller. Mathematically, a function f is decreasing on an interval I if for every x1 < x2​ in I, f (x1) > f (x2). This type of behavior is visually identified on a graph that slopes downward from left to right.The nature of a function can be analyzed by calculating...
267
Factors Affecting Activity Coefficient01:17

Factors Affecting Activity Coefficient

1.6K
The extended Debye-Hückel equation indicates that the activity coefficient of an ion in an aqueous solution at 25°C depends on three partially interdependent properties: the ionic strength of the solution, the charge of the ion, and the ion size. 
The activity coefficient value for an ion is close to one when the solution has almost zero ionic strength, i.e., when the solution shows close to ideal behavior. As the ionic strength of the solution increases from 0 to 0.1 mol/L, a...
1.6K
Decreased Body Temperature01:29

Decreased Body Temperature

1.0K
A decreased body temperature can occur in patients with hypothermia and frostbite. Heat loss with extended cold exposure overpowers the body's ability to create heat, resulting in hypothermia. Core temperature readings help classify hypothermia. Mild hypothermia is temperatures between 32 °C (89.6 °F) and 35°C (95 °F) and is caused by impaired thermoregulation. Moderate hypothermia is temperatures between 28 C (82.4 °F) and 32 °C (89.6 °F) caused by...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Precipitation-Based Encapsulation of Fibrinogen in Calcium Carbonate for Non-Compressible Hemorrhage Control.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

SORTing out gene editing therapies for neuromuscular disorders.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Plasmin-mediated fibrinolysis is required for hematopoietic recovery after 5-FU-induced myeloablation.

Blood advances·2026
Same author

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same author

The Elephant in the Room: The High Cost of High Achievement.

Journal of vascular and interventional radiology : JVIR·2026
Same author

Anti-fibrinolytic strategies improve liver regeneration in mice and reduce post-hepatectomy liver failure in patients.

Blood·2026

Related Experiment Video

Updated: Jan 29, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

17.9K

Coagulation factor XIII-A and activated FXIII-A decrease in some deep vein thrombosis patients following

Woosuk S Hur1, Hannah Warner2, Lindsay Machan2

  • 1Michael Smith Laboratories, Department of Biochemistry and Molecular Biology, University of British Columbia.

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|February 15, 2019
PubMed
Summary

Tissue plasminogen activator used in catheter-directed thrombolysis (CDT) can degrade coagulation factor XIII (FXIII). This FXIII reduction may contribute to bleeding risks associated with thrombolytic therapy.

More Related Videos

Stenosis of the Inferior Vena Cava: A Murine Model of Deep Vein Thrombosis
05:37

Stenosis of the Inferior Vena Cava: A Murine Model of Deep Vein Thrombosis

Published on: December 22, 2017

25.8K
Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography
06:44

Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography

Published on: April 13, 2018

10.5K

Related Experiment Videos

Last Updated: Jan 29, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

17.9K
Stenosis of the Inferior Vena Cava: A Murine Model of Deep Vein Thrombosis
05:37

Stenosis of the Inferior Vena Cava: A Murine Model of Deep Vein Thrombosis

Published on: December 22, 2017

25.8K
Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography
06:44

Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography

Published on: April 13, 2018

10.5K

Area of Science:

  • Biochemistry
  • Hematology
  • Thrombosis Research

Background:

  • Thrombolytic therapy, including catheter-directed thrombolysis (CDT), is crucial for treating thrombotic events but carries risks of severe bleeding.
  • The precise mechanisms underlying major bleeds and intracerebral hemorrhages during thrombolysis remain incompletely understood.
  • Coagulation factor XIII (FXIII), particularly its activated form (FXIII-A), plays a key role at the interface of coagulation and fibrinolysis.

Purpose of the Study:

  • To investigate the impact of tissue plasminogen activator (tPA) administration during CDT on the stability and levels of coagulation factor XIII (FXIII).
  • To explore the potential role of FXIII alterations in the bleeding complications associated with thrombolytic therapy.

Main Methods:

  • Analysis of FXIII and FXIII-A stability using purified proteins.
  • Measurement of FXIII and FXIII-A levels in blood samples from nine deep vein thrombosis patients undergoing CDT.
  • Sample collection immediately before, immediately after, and one day post-thrombolysis.

Main Results:

  • Purified tPA was found to directly degrade FXIII-A.
  • During CDT, FXIII levels decreased by over 40% in five of nine patients.
  • FXIII-A levels showed a significant decrease (over 85%) in two patients during activated thrombolysis.

Conclusions:

  • CDT-administered tPA can lead to a reduction in FXIII and FXIII-A levels in some patients.
  • The observed decrease in FXIII-A during CDT suggests a potential link to bleeding complications.
  • Further research is warranted to elucidate the specific role of FXIII-A in thrombolysis-associated bleeding.